Momenta Pharmaceuticals, Inc. Announces Presentation of Data Supporting Clinical Development of Novel Oncology Drug Candidate M402
Published: Jun 04, 2012
CHICAGO, June 4, 2012 (GLOBE NEWSWIRE) -- Preclinical data for M402, a novel oncology drug candidate being developed by Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), showed that M402 in combination with gemcitabine prolonged survival and substantially lowered the incidence of metastasis in two pancreatic cancer models. The data were presented today in a poster presentation at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The poster presented preclinical data showing the potential of a future clinical approach for the treatment of patients with metastatic pancreatic cancer combining a drug candidate that targets multiple cancer biology pathways with standard of care chemotherapy treatment.